pridopidine
Sign in to saveAlso known as 4-[3-(methanesulfonyl)phenyl]-1-propylpiperidine
Pridopidine (developmental code name PL-101) is an orally administrated small molecule investigational drug. Pridopidine is a selective and potent sigma-1 receptor agonist. It is being developed by Prilenia Therapeutics and is currently in late-stage clinical development for Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS).
Wikidata facts
- Mass
- 281.145
Show 3 more facts
- chemical formula
- C₁₅H₂₃NO₂S
- World Health Organisation international non-proprietary name
- بريدوبيدين
- canonical SMILES
- CCCN1CCC(CC1)C2=CC(=CC=C2)S(=O)(=O)C
Sources (2)
via Wikidata · CC0
~5 min read
Article
10 sectionsContents
- Mechanism of action
- Chemistry
- Analogues
- Potential indications
- Huntington's disease
- Amyotrophic lateral sclerosis
- Society and culture
- Legal status
- See also
- References
Pridopidine (developmental code name PL-101) is an orally administrated small molecule investigational drug. Pridopidine is a selective and potent sigma-1 receptor agonist. It is being developed by Prilenia Therapeutics and is currently in late-stage clinical development for Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS).
== Mechanism of action == Pridopidine works by binding and activating an intracellular protein called the sigma-1 receptor (S1R) located at the mitochondria-associated membrane (MAM) of the endoplasmic reticulum. The S1R regulates key cellular processes crucial to neuronal health and survival. Selective activation of the S1R is a promising therapeutic target for treating neurodegenerative and neurodevelopmental disorders.